Celtic Pharma

Celtic Pharma

Celtic Pharma was founded in 2004 by Stephen Evans-Freke, a veteran biotechnology financier who previously co-founded SG Cowen's healthcare banking franchise, alongside John Mayo, the former finance director of Glaxo Wellcome. The firm emerged from the premise that pension funds and sovereign wealth investors needed a specialized vehicle to access pharmaceutical royalties and late-stage clinical assets — a strategy distinct from traditional biotech venture capital. Evans-Freke had already established a track record in the space through Royalty Pharma, the dominant player in drug-royalty acquisitions, and Celtic became a separate, actively managed platform operating from London. The firm acquires royalty streams, revenue interests, and direct ownership stakes in approved and Phase III pharmaceutical products. Target assets include therapies for oncology, infectious disease, and neurology. Celtic Pharma does not operate as a fund-of-funds and rarely participates in early-stage venture rounds; it underwrites the regulatory and reimbursement risk on single assets, structuring transactions directly with originator biotech companies or their lenders. Confirmed historical positions include royalties on ustekinumab (Stelara) and certolizumab pegol (Cimzia), both blockbuster immunology drugs (public record, per EvaluatePharma). The firm's geographic focus centers on products approved in the United States and major European markets. Team size and total deployment remain undisclosed. The firm has not raised blind-pool funds in the traditional private equity model; it structures transactions on an asset-by-asset basis. This architecture allows Celtic to bypass the fundraising cycle and align capital calls with specific milestones. In recent years, the firm established Celtic Pharma Management LP, a Delaware-registered entity, to manage certain US-facing royalty acquisitions — a structural adaptation to a portfolio increasingly weighted toward North American assets (public record, per SEC filings). No adjacent philanthropic vehicles or membership clubs have been disclosed. The firm's structural distinction lies in its pure-play asset finance model. Unlike most healthcare private equity managers that take equity in operating companies — with their attendant clinical, regulatory, and management burdens — Celtic underwrites specific drug revenue curves. This allows pension fund and sovereign wealth allocators to access pharmaceutical cash flows without the J-curve dynamics of traditional biotechnology fund commitments. The approach leans heavily on the actuarial pricing of FDA-approved or advanced-stage products, a skill set that more closely resembles specialty insurance underwriting than venture capital portfolio management.